- Market capitalisation of €175.914 million
Euronext today congratulates ONWARD Medical on its additional listing on Euronext Paris (ticker code: ONWD). ONWARD Medical is also listed on Euronext Brussels and Euronext Amsterdam.
ONWARD Medical is a technology company creating innovative spinal cord stimulation therapies[1] to restore movement, function, and independence in people with spinal cord injury (SCI). The company closely works with CEA-Climatec, a world renowned biomedical research institute based in Grenoble (France), funded by the French government. The two companies are leading clinical research by combining the investigational WIMAGINE® BCI interface from CEA-Clinatec with the investigational ONWARD ARC-IM® System (an implanted technology that delivers targeted stimulation to the spinal cord) to create a DigitalBridge™ across the injured spinal cord. This investigational system is named ARC-BCI™.
On 19 September 2024, the company announced that the most recent participant to its study had been implanted with the ARC-BCI System to restore lower limb mobility after spinal cord injury. The implant procedure was performed on September 12, 2024, by Jocelyne Bloch, MD, head of functional neurosurgery at Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland.
The market capitalisation of ONWARD Medical is made of 34 628 832 ordinary shares. At market close on 23 September 2024, the share price of the company was at €5.08 per share. ONWARD Medical market capitalisation at market close on 23 September 2024 was of €175.914 million.
Dave Marver, CEO of ONWARD Medical, said: “We are extremely proud to be facilitating trading of ONWARD Medical shares by making them available on Euronext Paris. Our company benefits from a special link with France, highlighted by our crucial collaboration on brain-computer interface research with CEA-Clinatec. This listing provides greater access to French investors, thereby supporting our efforts to address the significant unmet needs of people suffering from spinal cord injuries in France and around the world.”
Caption: Dave Marver, CEO of ONWARD Medical, rang the bell this morning in the presence of his teams and of Alain Baetens, Corporate Sales Director to celebrate the listing on Euronext Paris of ONWARD Medical.